Large opportunity Biotech investors and patients point to a substantial addressable market in neuroinflammatory and autoimmune diseases; leverage this to approach payers, pharma partners, and research collaborations for ANX005 ANX007 and ANX009 in CNS, visual, and autoimmune indications.

Strategic partnerships Oxford Finance credit facility and non-dilutive financing signals a readiness to collaborate with strategic lenders and potential co-development or regional commercialization partners; initiate discussions with financial and strategic consultancies to accelerate global rights and manufacturing partnerships.

Clinical momentum Lead programs vonaprument and tanruprubart are advancing in neuroinflammatory indications with presentations at Retina Society meetings; pursue opportunities for investigator-led trials, adjunctive studies, and companion diagnostic collaborations to broaden data generation and market adoption.

Payer and access focus Significant funding and a biomarker-driven strategy imply a willingness to engage early with health technology assessment bodies; propose value dossiers, biomarker-based endpoints, and real-world data plans to support reimbursement and rapid patient access.

Global commercialization Recent financing supports international commercialization plans; identify regional partners in Europe, Asia-Pacific, and the Americas, offering co-development, distribution rights, and local regulatory support to expand reach for intravitreal, intravenous, and subcutaneous C1q-targeted therapies.